Hybribio Biotech announces new board, leadership appointments

Guangdong Hybribio Biotech held its first extraordinary general meeting of shareholders and a subsequent sixth board of directors' first meeting on September 10, 2025. Key resolutions passed include amendments to the company's articles of association, shareholder meeting rules, and board meeting rules, as well as new fundraising management and related party transaction management systems. All these were passed by a two-thirds majority of votes.

The shareholders elected the sixth board of directors, comprising five non-independent directors (Mr. Guan Qiaozhong, Mr. Huang Weixiong, Ms. Wang Jianyu, Mr. Guan Zhichao, Ms. Yang Xiaoyan), three independent directors (Mr. Chen Yingshi, Mr. Qiao Youlin, Mr. Yang Chunxue), and one employee representative director (Mr. Xie Longxu). Following this, the new board appointed Mr. Guan Qiaozhong as chairman and Mr. Huang Weixiong as vice chairman, with Ms. Wang Jianyu as general manager.

Additionally, the board established four special committees and appointed members. They also appointed other senior management, including Mr. Guan Zhichao as executive deputy general manager, Mr. Li Xiaochuan as chief medical officer, Mr. Chen Yi and Ms. Weng Danrong as deputy general managers, Mr. Chen Yi as board secretary, Mr. Li Qinghui as chief financial officer, and Ms. Yuan Xian as securities affairs representative. Mr. Wang Bin was appointed as the head of the internal audit department.